United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News GNI Group to halt enrolment in Phase 2 liver fibrosis trial following positive results Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2… bypharmanewsdailyOctober 2, 2018
